Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H11O2.Na |
| Molecular Weight | 138.1401 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CCC(C)(C)C([O-])=O
InChI
InChIKey=OOPXYEYPPHJHSE-UHFFFAOYSA-M
InChI=1S/C6H12O2.Na/c1-4-6(2,3)5(7)8;/h4H2,1-3H3,(H,7,8);/q;+1/p-1
| Molecular Formula | C6H11O2 |
| Molecular Weight | 115.1503 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
2,2-DIMETHYLBUTYRIC ACID (HQK-1001) is an orally administered SCFAD (Short Chain Fatty Acid Derivative), which has shown an excellent safety profile and biologic effects on fetal hemoglobin induction and red blood cell production in the laboratory, relevant animal models, and in clinical trials carried out in healthy human subjects as well as patients with sickle cell disease and beta thalassemia. The compound has received Orphan Drug Designation in the United States and Europe for both sickle cell disease and beta thalassemia. HemaQuest Pharmaceuticals was developing HQK-1001 for the oral treatment of sickle cell anaemia and beta thalassaemia. HQK-1001 has been evaluated in phase II trials for beta thalassaemia and sickle cell anaemia.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Fetal globin gene inducers: novel agents and new potential. | 2010-08 |
|
| Beta-thalassemia. | 2010-05-21 |
|
| Biotechnological production and applications of statins. | 2010-01 |
|
| Liquid chromatography-mass spectrometric assay for quantitation of the short-chain fatty acid, 2,2-dimethylbutyrate (NSC 741804), in rat plasma. | 2008-02-01 |
|
| Top-down systems biology integration of conditional prebiotic modulated transgenomic interactions in a humanized microbiome mouse model. | 2008 |
|
| Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model. | 2008 |
|
| A top-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model. | 2007 |
|
| Novel short chain fatty acids restore chloride secretion in cystic fibrosis. | 2006-03-31 |
|
| New polynuclear manganese clusters from the use of the hydrophobic carboxylate ligand 2,2-dimethylbutyrate. | 2005-06-27 |
|
| Simvastatin. | 2003-08 |
|
| [Chemical components of essential oils from the herb of Ligularia virgaurea]. | 2003-07 |
|
| Differential effects of short-chain fatty acids on head and neck squamous carcinoma cells. | 2002-04 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23828223
Hemoglobin SS or S/β(0) thalassemia: HQK-1001 was administered daily for 26 weeks at 30 mg/kg (n = 15), 40 mg/kg (n = 18) and 50 mg/kg (n = 19), either alone (n = 21) or with hydroxyurea (n = 31).
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:29:50 GMT 2025
by
admin
on
Mon Mar 31 18:29:50 GMT 2025
|
| Record UNII |
XKM99SPB5I
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
265108
Created by
admin on Mon Mar 31 18:29:50 GMT 2025 , Edited by admin on Mon Mar 31 18:29:50 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/09/621
Created by
admin on Mon Mar 31 18:29:50 GMT 2025 , Edited by admin on Mon Mar 31 18:29:50 GMT 2025
|
||
|
FDA ORPHAN DRUG |
259608
Created by
admin on Mon Mar 31 18:29:50 GMT 2025 , Edited by admin on Mon Mar 31 18:29:50 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3934-02-9
Created by
admin on Mon Mar 31 18:29:50 GMT 2025 , Edited by admin on Mon Mar 31 18:29:50 GMT 2025
|
PRIMARY | |||
|
53247304
Created by
admin on Mon Mar 31 18:29:50 GMT 2025 , Edited by admin on Mon Mar 31 18:29:50 GMT 2025
|
PRIMARY | |||
|
100000178199
Created by
admin on Mon Mar 31 18:29:50 GMT 2025 , Edited by admin on Mon Mar 31 18:29:50 GMT 2025
|
PRIMARY | |||
|
SUB193821
Created by
admin on Mon Mar 31 18:29:50 GMT 2025 , Edited by admin on Mon Mar 31 18:29:50 GMT 2025
|
PRIMARY | |||
|
XKM99SPB5I
Created by
admin on Mon Mar 31 18:29:50 GMT 2025 , Edited by admin on Mon Mar 31 18:29:50 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|